FAM177B: A Potential Drug Target with Unique Structure and Multiple Domains

Target Name: FAM177B

NCBI ID: G400823

FAM177B

FAM177B: A Potential Drug Target with Unique Structure and Multiple Domains

The protein FAM177B, also known as FAM177B-CS1, is a member of the FAM177 family of proteins that are characterized by their unique structure and the presence of a characteristic domains such as a nucleotide-binding oligomerization domain (NBO), a zinc finger, and a leucine-rich repeat (LRR) domain. FAM177B is a 21-kDa protein that is expressed in various tissues of the human body, including the brain, heart, and skeletal muscles.

The FAM177B protein has been identified as a potential drug target due to its unique structure and the presence of multiple domains that are involved in various cellular processes. One of the most interesting aspects of FAM177B is its NBO domain, which is known to play a role in the regulation of gene expression and to be involved in the assembly of RNA-protein complexes. This domain is also known to be involved in the regulation of protein stability and to be involved in the modulation of cellular signaling pathways.

Another interesting domain present in FAM177B is the zinc finger domain, which is known to play a role in the regulation of gene expression and to be involved in the assembly of RNA-protein complexes. This domain is also known to be involved in the regulation of protein stability and to be involved in the modulation of cellular signaling pathways.

FAM177B also has a leucine-rich repeat (LRR) domain, which is known to play a role in the regulation of protein structure and to be involved in the assembly of RNA-protein complexes. This domain is also known to be involved in the regulation of protein stability and to be involved in the modulation of cellular signaling pathways.

The FAM177B protein is also known to have a nucleotide-binding oligomerization domain (NBO), which is known to play a role in the regulation of gene expression and to be involved in the assembly of RNA-protein complexes. This domain is also known to be involved in the regulation of protein stability and to be involved in the modulation of cellular signaling pathways.

FAM177B is a 21-kDa protein that is expressed in various tissues of the human body, including the brain, heart, and skeletal muscles. It is characterized by its unique structure, including a NBO domain, a zinc finger domain, and an LRR domain, as well as its role in the regulation of gene expression and the assembly of RNA-protein complexes. These properties make FAM177B a promising drug target for the development of new therapeutic strategies for various diseases.

In conclusion, FAM177B is a unique and fascinating protein that has been identified as a potential drug target due to its unique structure and the presence of multiple domains involved in various cellular processes. The NBO, zinc finger, and LRR domains, as well as its role in the regulation of gene expression and the assembly of RNA-protein complexes, make FAM177B a promising target for the development of new therapeutic strategies for various diseases. Further research is needed to understand the full potential of FAM177B as a drug target and to develop new therapeutic strategies for the treatment of diseases associated with its dysfunction.

Protein Name: Family With Sequence Similarity 177 Member B

The "FAM177B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM177B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets